The Future of Progressive Multiple Sclerosis Therapies

Area of Science:

• Neurology
• Immunology
• Neuroscience

Background:

• Multiple sclerosis (MS) impacts over a million individuals in the US, with a substantial number experiencing primary progressive MS or transitioning to secondary progressive MS.
• Progressive MS is the primary driver of disability accumulation, necessitating targeted therapeutic strategies.
• While treatments for relapsing MS have advanced, therapies for progressive forms remain limited, highlighting a critical unmet medical need.

Purpose of the Study:

• To review challenges in developing therapies for progressive multiple sclerosis (MS).
• To assess current treatment options for progressive MS and therapies in development.
• To consider patient-specific factors, including the potential discontinuation of therapy.

Main Methods:

• Literature review of challenges in progressive MS therapy development.
• Assessment of evidence for approved therapies in progressive MS.
• Identification of ongoing clinical trials and therapeutic candidates for progressive MS.
• Discussion of treatment cessation strategies for specific patient profiles.

Main Results:

• Significant challenges exist in developing effective disease-modifying therapies for progressive MS.
• Current evidence for approved therapies in progressive MS is limited, with ongoing research exploring new treatment avenues.
• Understanding the neuroinflammatory and neurodegenerative mechanisms is key to advancing treatment options.

Conclusions:

• Developing disease-modifying therapies to mitigate neurologic disability in progressive MS is a critical unmet need.
• Advancements in understanding MS pathophysiology offer potential for improved treatments.
• Personalized therapeutic approaches, including careful consideration of treatment discontinuation, are important for managing progressive MS.